Opthea(NASDAQ) OPT

Current PriceN/A

Market CapN/A

Since IPO (2012)-99%

5 Year-100%

1 Year-99%

1 Month+69%

Opthea last closing stock price
Metric	Price	Date
Last close	USD 0.03	2026-07-22

Opthea stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.03	2026-07-15
1 month	+69.15%	USD 0.02	2026-06-22
3 month	-30.26%	USD 0.05	2026-04-23
Year to date	+44.93%	USD 0.02	2025-12-31
1 year	-99%	USD 3.41	2025-03-17
3 year	-98.92%	USD 3.16	2023-07-21
5 year	-99.56%	USD 7.73	2021-07-23
Since inception	-99.29%	USD 3.95	2012-04-12

Opthea Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$298.80K

Net Income (TTM)

-$435.22M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 28, 2025

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 28, 2025

OPT News

Why Opthea Stock Skyrocketed Today

Keith SpeightsJun 16, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Opthea

Opthea Limited is dedicated to advancing therapies for eye diseases, specifically wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company uses a dual-action scientific approach that targets both VEGF and FGF pathways to address these conditions. This innovative method aims to meet significant unmet needs in the field of ophthalmology.

Products and Services

OPT-302: A lead product candidate for treating wet AMD and DME.

What Makes Opthea Limited Special

Opthea sets itself apart with its dual-action mechanism targeting VEGF and FGF pathways, which may improve outcomes for retinal disease patients. This approach distinguishes the company from others focused solely on VEGF inhibition.

Five Things You Need to Know

Opthea Limited focuses on innovative therapies for ophthalmic diseases like wet AMD and DME.

The company combines VEGF and FGF inhibition in its treatments, offering a unique therapeutic approach.

Its lead product candidate, OPT-302, is in late-stage clinical trials.

Opthea's leadership team has extensive expertise in drug development and commercialization.

The company seeks strategic partnerships to expand market reach and accelerate development timelines.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Frédéric Guerard, PharmD

Website

www.opthea.com

Headquarters

South Yarra, VIC 3141, AU

OPT Financials

Key Financial Metrics (TTM)

Gross Margin

100.31%

Operating Margin

14657.23%

Net Income Margin

-128871.09%

Return on Equity

-312.02%

Return on Capital

-336.81%

Return on Assets

1168.69%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$71.79K

Operating Income

-$492.24M

EBITDA

-$360.76M

Operating Cash Flow

-$295.72M

Capital Expenditure

-$46.70K

Free Cash Flow

-$318.23M

Cash & ST Invst.

$31.74M

Total Debt

$161.82M

Opthea Performance Analysis

Opthea annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-06-30	USD 90,358	N/A
2023	2023-06-30	USD 107,917	19.4%
2024	2024-06-30	USD 125,106	15.9%
2025	2025-06-30	USD 24,957	-80.1%

Opthea sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2023-12-31	11.8%
Q4	2024-06-30	-36.0%
Q2	2024-12-31	150.0%
Q4	2025-06-30	-102.0%

Opthea annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-06-30	USD -1.83	N/A
2023	2023-06-30	USD -2.23	21.8%
2024	2024-06-30	USD -2.77	24.4%
2025	2025-06-30	USD -1.06	-61.7%

Opthea sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2023-12-31	-25.0%
Q4	2024-06-30	28.0%
Q2	2024-12-31	-16.7%
Q4	2025-06-30	88.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

-$2.99K

-103.6%

Gross Profit

-$2.99K

+93.3%

Gross Margin

100.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$32.38M

+66.6%

EBITDA

-$8.47M

+92.1%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Total Cash

$31.74M

-64.4%

Total Debt

$161.82M

+88956.2%

Accounts Receivable

$4.98M

-24.1%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$161.82M

+66239.3%

Return on Assets

11.69%

N/A

Return on Invested Capital

-1.40%

N/A

Free Cash Flow

-$88.89M

-18.3%

Operating Cash Flow

-$56.61M

+24.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

MRTXMirati Therapeutics, Inc.

MRTXMirati Therapeutics, Inc.$58.70-0.17%

ALPNAlpine Immune Sciences, Inc.

ALPNAlpine Immune Sciences, Inc.$64.97+0.02%

RYZBRayzeBio, Inc. Common Stock

RYZBRayzeBio, Inc. Common Stock$62.49+0.02%

CBAYCymaBay Therapeutics, Inc.

CBAYCymaBay Therapeutics, Inc.$32.48+0.03%

SWTXSpringWorks Therapeutics, Inc.

SWTXSpringWorks Therapeutics, Inc.$46.99+0.02%

ISEEIVERIC bio, Inc.

ISEEIVERIC bio, Inc.$39.95+0.38%

SYNHSyneos Health, Inc.

SYNHSyneos Health, Inc.$42.98+0.02%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$10.96-0.02%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$40.94+0.02%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$70.28-0.02%

NOKNokia

NOKNokia$10.30-0.03%

ONDSOndas

ONDSOndas$8.00+0.04%

IRENIren

IRENIren$41.28-0.00%

SMRNuScale Power

SMRNuScale Power$8.68-0.00%

Questions About OPT

What is the current price of Opthea?

Opthea is trading at N/A per share.

What is the 52-week range for Opthea?

Over the past 52 weeks, Opthea has traded between N/A and N/A.

How much debt does Opthea have?

As of the most recent reporting period, Opthea reported total debt of $246.99M.

How much cash does Opthea have on hand?

Opthea reported $48.44M in cash and cash equivalents in its most recent financial results.

What is Opthea’s dividend yield?

Opthea does not currently have a dividend yield.

Opthea(NASDAQ) OPT

Opthea Financials at a Glance

OPT News

Why Opthea Stock Skyrocketed Today

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Opthea

Products and Services

What Makes Opthea Limited Special

Five Things You Need to Know

OPT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Opthea Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About OPT

What is the current price of Opthea?

What is the 52-week range for Opthea?

How much debt does Opthea have?

How much cash does Opthea have on hand?

What is Opthea’s dividend yield?

Premium Investing Services